All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Moving From Passive to Active Clinical Trials Enrollment

January 29th 2024

The Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.

Outreach and Engagement: Colleagues Come Together to Improve Community Care

January 29th 2024

Kiara Ellis, MSW, details community outreach and engagement conversations centered around key matters affecting NCI-designated cancer centers.

Morphologic Type and Tumor Stage May Inform Real-World Outcomes in RCC

January 28th 2024

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Subcutaneous Nivolumab Provides Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

January 27th 2024

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Adjuvant Pembrolizumab Significantly Prolongs OS vs Placebo in ccRCC

January 27th 2024

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Extended Follow-Up Confirm Efficacy of First-Line Pembrolizumab/Lenvatinib Combo in Advanced Non–Clear Cell RCC

January 27th 2024

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Network Meta-Analysis Sheds Light on Efficacy of Lenvatinib Plus Pembrolizumab Vs SOC in Advanced RCC

January 27th 2024

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan Improves Symptoms and Extends Time to Treatment Deterioration in Advanced RCC

January 27th 2024

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Adjuvant Pembrolizumab Improves DFS, But Not OS, in Locally Advanced/Muscle-Invasive Urothelial Carcinoma

January 27th 2024

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab Maintains Survival Advantage Across Advanced Urothelial Cancer Subgroups

January 27th 2024

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

Frontline Pembrolizumab Plus Cabozantinib Elicits Responses in Cisplatin-Ineligible Urothelial Carcinoma

January 27th 2024

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Urinary MRD Status Potentially Predictive of Recurrence in BCG-Unresponsive NMIBC

January 26th 2024

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

January 26th 2024

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies.

CA-125 KELIM Score May Predict Efficacy in Patients With Epithelial Ovarian Cancer Receiving HIPEC During Surgery

January 26th 2024

Gabriella Smith, MD, discusses the potential impact of CA-125 KELIM score for patients with epithelial ovarian cancer undergoing HIPEC during surgery.

Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies

January 26th 2024

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Real-World Data Confirm the Incidence of ADC-Related Ocular Toxicities in Ovarian Cancer

January 26th 2024

Susan Marie Lang, MD, discusses real-world data on the incidence of ocular toxicities in patients with ovarian cancer receiving mirvetuximab soravtansine.